Abstract The orexigenic peptide ghrelin plays a prominent role in the regulation of energy balance and in the mediation of reward processes and reinforcement for addictive drugs, such as nicotine. Nicotine is the principal psychoactive component in tobacco, which is responsible for addiction and relapse of smokers. Ghrelin and nicotine activates the mesolimbicocortical dopaminergic pathways via growth hormone secretagogue receptors (GHS-R1A) and nicotinic acetylcholine receptors (nAchR), respectively, resulting in the release of dopamine in the nucleus accumbens, the amygdala and the prefrontal cortex. In the present study an in vitro superfusion of rat amygdalar slices was performed in order to investigate the direct action of ghrelin and nicotine on the amygdalar dopamine release. Ghrelin increased significantly the dopamine release from the rat amygdala following electrical stimulation. This effect was inhibited by both the selective GHS-R1A antagonist GHRP-6 and the selective nAchR antagonist mecamylamine. Under the same conditions, nicotine also increased significantly the dopamine release from the rat amygdala. This effect was antagonized by mecamylamine, but not by GHRP-6. Co-administration of ghrelin and nicotine induced a similar increase of amygdalar dopamine release. This stimulatory effect was partially reversed by both GHRP-6 and mecamylamine. The present results demonstrate that both ghrelin and nicotine stimulates directly the dopamine release in the amygdala, an important dopaminergic target area of the mesolimbicocortical pathway.
Introduction
Ghrelin is a 28-amino acid orexigenic peptide, which was originally isolated from the rat stomach [1, 2] . It acts on the growth hormone secretagogue receptor (GHS-R), which has two isoforms (GHS-R1A and GHS-R1B) [3] . GHS-R1A, apart from GH release, was proved to mediate food intake and energy balance, reward, addiction, memory, arousal and neuroprotection [4] . GHS-R1B is thought to regulate/inhibit the actions of GHS-R1A [5] .
Nicotine is the principal psychoactive component in tobacco, which is responsible for addiction and relapse of smokers [6] . Nicotine exerts its effects on the central nervous system by the activation of nicotinic acetylcholine receptors (nAchRs) [7] . The dopaminergic neurons of the mesencephalon express a variety of nAchR subtypes which, when activated by nicotine, promote a sustained increase in dopamine release in the target areas. This process was found essential to the development of nicotine addiction [8] and could be inhibited by the non-selective, competitive nAchR antagonist mecamylamine [9] .
Nicotine, infused directly into the dopaminergic target areas, elevates dopamine release from the nerve terminals and this effect is blocked by mecamylamine [9] . The principal dopaminergic pathways arise from the mediobasal hypothalamus (tuberoinfundibular pathway), ventral tegmental area (VTA, mesolimbicocortical pathways) and the substantia nigra (mesostriatal pathway) [10] . The VTA gives rise to the mesolimbicocortical pathway and innervates the nucleus accumbens (NAcc), the amygdala, especially the central (CeA) and the basolateral (BLA) amygdalar nuclei and the prefrontal cortex [11] [12] [13] .
Previous articles suggested that ghrelin activates the cholinergic-dopaminergic reward link [14] [15] [16] . This reward link encompasses the cholinergic afferent projection from the laterodorsal tegmental area (LDTg) to the VTA and the dopaminergic mesolimbic pathway projecting from the VTA to the NAcc [17] . Several lines of evidence support that this link mediates the reward and reinforcement for both natural and artificial rewards and addictive drugs, such as nicotine [18] [19] [20] . Ghrelin presumably, via activation of this reward link, increases the incentive value of motivated behaviors such as reward seeking [16] .
Recent articles demonstrated that ghrelin has a prominent impact on the amygdala, an important dopaminergic target area of the mesolimbicocortical pathway [21] [22] [23] . The role of amygdala in reward mechanisms and drug addiction is underlined by the anatomical concept of the extended amygdala circuit, which consists of the central nucleus of amygdala (CeA), the bed nucleus of stria terminalis (BNST) and the shell of NAcc [12] . The nuclei of extended amygdala circuit have similar cell morphology, immunohistochemistry, and common afferent (VTA and limbic areas, such as the hippocampus, the basolateral amygdala (BLA), the midbrain, and the lateral hypothalamus) and efferent projections (VTA, the ventral pallidum, the brainstem and the lateral hypothalamus) [24] modulating drug reward and addiction to drugs, such as nicotine [25, 26] .
Recently published studies have focused upon the action of ghrelin on the accumbal dopamine release and its interaction with addictive drugs. In these studies, ghrelin was administered peripherally, intracerebroventricularly or locally, into the LDTg or the VTA [14] [15] [16] . However, these studies provided no evidence about the direct effect of ghrelin on the dopaminergic target areas of the VTA, such as the amygdala. Therefore, in this study an in vitro superfusion of rat amygdalar slices was performed in order to investigate the action of ghrelin and nicotine on the amygdalar dopamine release. In the present experiments ghrelin and nicotine were applied directly into the amygdala, in single or in co-administration.
Materials and Methods

Animals Used
Male Wistar rats weighing 150-250 g were used. During the experiments every effort was made to limit the number of animals used, and to minimize animal suffering. The animals were kept according to the rules of the Ethical 
Experimental Procedures
An in vitro superfusion method [27, 28] was utilized to determine the effects of ghrelin and nicotine on amygdalar dopamine release. The rats were decapitated and their brains were rapidly removed. The amygdalae were isolated and dissected in a Petri dish filled with ice-cold Krebs solution. The amygdalae were prepared according to the Stereotaxic atlas of the rat brain [29] . The left and right poles of the temporal lobes were dissected in the frontal plane at the anterior (approximately 1.5 mm rostrally from the bregma) and the posterior (approximately 2 mm caudally from the bregma) borders of the amygdalae. The amygdalae were then decapsulated from the surrounding white matter with the help of a stereomicroscope. External skull reference values were extrapolated to brain coordinates using the limits of the hemispheres such as, the anterior poles and the fissure between the cerebrum and the cerebellum. In the sagittal plain, the bregma is approximately in 4 mm distance from the anterior pole, therefore the reference coordinates can be calculated with subtracting 4 mm from the bregma value according to the abscissa. The extracted amygdalae were cut with a McIlwain tissue chopper and slices of 300 lM were produced. The slices were incubated for 30 min in 8 ml of Krebs solution, submerged in a water bath at 37°C and gassed through a single use needle with a mixture of 5 % CO 2 and 95 % O 2 . During the incubation, the medium was supplemented with 0.15 lmol [ 3 H]DA. The total amount of radioactivity used for labeling tissue dopamine stores was 0.042 lCi/ml and the tissue content of radioactivity was 0.386 lCi/ml. Two tritiated slices were transferred to each of the four cylindrical perspex chambers of the superfusion system (Experimetria Ltd., Hungary). A multichannel peristaltic pump (Gilson Minipuls 2) was used to maintain a constant superfusion rate of 300 ll/min. The superfusion was performed for 30 min to allow tissue equilibrium, then the samples were collected for 32 min in Eppendorf tubes by a multichannel fraction collector (Gilson FC 203B). 20 min prior to sample collecting, the slices were pretreated with 100 lM mecamylamine or with 1 lM GHRP-6. 10 min prior to sample collecting, the slices were treated with 1 lM ghrelin, 100 lM nicotine or combined. Gold electrodes were attached to both halves of the superfusion chambers and connected to an ST-02 electrical stimulator (Experimetria Ltd., Hungary). Two minutes after the sample collection had started, electrical stimulation consisting of square-wave impulses (total duration: 2 min, voltage: 100 V, pulse length: 5 ms, frequency: 10 Hz) were delivered to each of the four chambers. The remnants of the superfused brain slices were solubilized in 200 ml of Krebs solution, using an ultrasonic homogenizer (Branson Sonifier 250, Labequip Ltd., Canada). The radioactivity in the fractions and the homogenized tissue samples was measured with a liquid scintillation spectrometer (Tri-carb 2100TR, Packard, USA) and expressed in count per minute (CPM) after the addition of 3 ml of scintillation fluid (Ultima Gold, Perkin Elmer Inc., USA). 16 fractions were collected and 200 ll were extracted from each fraction to determine the fractional [ 3 H]DA release. The fractional [ 3 H]DA release was calculated as percentage of the radioactivity present in the collected sample relative to the total radioactivity of the corresponding tissue. The statistical analysis was performed for each fraction, but the most significant differences have been observed at the 14 min fractions.
Statistical Analysis
Statistical analysis of the results was performed by repeated measure analysis of variance (RMANOVA, Statistica v5.0, StatSoft Inc.) followed by Tukey's post hoc comparison test. Only the mean percentages were plotted and the standard error of the mean (SEM) is given in the figure captions. The differences between groups were examined by Tukey's post hoc comparison test, and a probability level of 0.05 or less was accepted as indicating a statistically significant difference.
Results
Ghrelin increased significantly the fractional (Fig. 1) .
Nicotine also increased significantly the fractional [ 3 H]DA release from rat amygdala slices following electrical stimulation [F 14min (1, 10) = 40.5000, p \ 0.05 for nicotine versus control]. This effect was inhibited significantly by mecamylamine [F 14min (1, 10) = 28.5480, p \ 0.05 for nicotine ? mecamylamine versus nicotine], but it was not influenced considerably by GHRP-6 [F 14min (1, 10) = 1.1732, p = 0.3041 for nicotine ? GHRP-6 versus nicotine] (Fig. 2) .
Ghrelin combined with nicotine elevated significantly the fractional 
Discussion
The present study demonstrates for the first time that ghrelin stimulates locally the dopamine release in the rat amygdala. This stimulation is mediated by GHS-R1A, as GHR-P6 inhibited completely the ghrelin-induced amygdalar dopamine release. There is a growing body of evidence revealing that ghrelin plays a prominent role in reward and reinforcement for both natural and artificial rewards and addictive drugs, such as nicotine [14, 16, 19] . Previous studies suggested that this role is accomplished by the activation of the cholinergic-dopaminergic reward link, which encompasses the afferent cholinergic projection from the LDTg to the VTA and the mesolimbic dopaminergic projection from the VTA to the NAcc [14] [15] [16] . Prior experiments showed that local administration of ghrelin into the LDTg or the VTA stimulates the dopamine release from the nerve terminals of the mesencephalic dopaminergic neurons, such as the NAcc [16, 18, 30] . The increase of accumbal dopamine release was reduced by different nicotinic receptor antagonists [16, 31] . Our experiments proved for the first time the direct action of ghrelin on the amygdalar dopamine release. This process can be either transmitted by presynaptic receptors or by cholinergic interneurons, which is supported by the inhibitory activity of selective nAchR antagonist. The amygdalar interaction of ghrelin with GABA and glutamate cannot be excluded either [22, 32] ; this is suggested by the residual activity observed in the presence of ghrelin and mecamylamine. The present study correlates with previous ones, demonstrating that nicotine stimulates the dopamine release in the terminal fields of the mesencephalic dopaminergic pathways, such as the ventral striatum (caudate-putamen), the dorsal striatum (NAcc) and the amygdala [33] [34] [35] . The stimulatory effect of nicotine is mediated by several nAchR subtypes expressed on dopaminergic cell bodies (a4a5b2, a4a6a5b2, a7) and on axon terminals (a4b2, a4a5b2, a6b2b3, a4a6b2b3) [6] . The latter ones are localized in these dopaminergic target areas, including the NAcc and amygdala, which represent the principal relay stations in the extended amygdala circuit [10, 12] . Along with the cholinergic-dopaminergic reward link, the extended amygdala circuit plays a prominent role in drug reward and drug addiction [16, 36] . Besides the functional correlation, there is a strong anatomical connection between these two systems. On one hand, the NAcc is a common nucleus of the two systems. On the other hand, the dopaminergic neurons of the VTA innervate each nuclei of the extended amygdala circuit (the NAcc, the BNST and the CeA) [10] . In addition, most of these nuclei express GHS-R1A and nAchRs [6, 22, 37, 38] (Fig. 4) . Mecamylamine blocked the effect of nicotine, without a doubt, significantly, but control (6) ghrelin+nicotine (6) ghrelin+nicotine+GHRP6 (6) ghrelin+nicotine+mecamylamine (6) electric impulse * ** ## Fig. 3 The effects of mecamylamine and GHRP-6 on the coadministered ghrelin and nicotine induced dopamine release in rat amygdala. Combined treatment with 1 lM ghrelin and 100 lM nicotine elevated significantly the fractional [3H]dopamine release from rat amygdala slices following electrical stimulation. This effect was reduced partially by pretreatment with both 100 lM mecamylamine and 1 lM GHRP-6. Values are presented as mean percentages ± SEM for each of the 2 min samples; the numbers in brackets indicate the numbers of slices. Statistical analysis of the results was performed by repeated measure analysis of variance (RMANOVA, Statistica v5.0, StatSoft Inc.) followed by Tukey's post hoc comparison test. *p \ 0.05 ghrelin ? nicotine versus control; ## p \ 0.05 ghrelin ? nicotine ? mecamylamine versus ghrelin ? nicotine; **p \ 0.05 ghrelin ? nicotine ? GHRP-6 versus ghrelin ? nicotine only partially. An explanation can be that other receptors, such as NMDA receptors, may be involved in the amygdalar action of nicotine, since nicotine increases NMDA receptor-mediated excitatory postsynaptic currents in rat CeA slices [38] . Another explanation can be that mecamylamine may also have a partial disinhibitory action on the amygdalar dopamine as the activation of nAchRs increases the frequency of GABAergic inhibitory postsynaptic currents in the BLA [39] .
Our experiments demonstrate that ghrelin and nicotine, in single or co-administration, stimulate equally the dopamine release in the amygdala, suggesting the role of both ghrelin and nicotine in drug reward and drug addiction [16, 40, 41] . According to our results the final common pathway should be the activation of cholinergic neurons since the specific cholinergic antagonist was able to block both the ghrelin-and the nicotine-induced dopamine response. Through direct or indirect activation of the CeA and the BLA ghrelin may increase the incentive value of motivated behaviors, such as reward seeking [16] . However, the intimate mechanism of rewarding action of ghrelin is yet to be elucidated. Our results may have clinical implications. Increased levels of ghrelin may increase the risk of smoking in adolescent females [41] . Moreover, patients with bulimia nervosa have elevated ghrelin levels and higher prevalence for nicotine dependence [42, 43] . Taking all these data into consideration, we share the opinion that ghrelin signaling may serve as a novel pharmacological target in the treatment of addictive disorders. as well. Both ghrelin and nicotine, by activating the mesolimbic dopaminergic pathways stimulate the dopamine release from the dopaminergic target areas. Our study demonstrates that ghrelin and nicotine, in single or co-administration, stimulate equally the dopamine release in the amygdala, consisted by the CeA, the basolateral (BLA) and the cortical (Cort) nuclei
